Advertisement

Pituitary

, Volume 14, Issue 1, pp 11–15 | Cite as

Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression

  • Ilan Shimon
  • Carlos Benbassat
  • Gloria Tzvetov
  • Simona Grozinsky-Glasberg
Article

Abstract

Men with hypogonadism tend to have low hemoglobin (HGB) levels. We have investigated a cohort of 36 consecutive male patients with macroprolactinomas to evaluate HGB during presentation and following treatment with cabergoline to suppress prolactin (PRL). Patients’ mean age at diagnosis was 48 years, the mean adenoma size measured 31 mm. The median PRL at baseline was 1,969 ng/ml; the mean testosterone level was low, 1.5 ng/ml. PRL had been successfully normalized in all but six men by using cabergoline. Mean baseline HGB at diagnosis was 13.1 gr%. Sixteen patients had HGB ≤ 13 gr%, including 4 men with HGB ≤ 11.5 gr%. In the subgroup of 15 men with very low testosterone (≤1 ng/ml), baseline HGB was 12.6 gr% compared with 13.5 gr% in patients with higher testosterone (P < 0.005). In 30 men in whom follow-up CBC data were available, mean baseline HGB increased from 13.2 to 13.9 gr% following PRL suppression by cabergoline. Baseline HGB levels inversely correlated with tumor size, reaching levels of 13.7 gr% in 10 men with macroprolactinomas of 10–20 mm in size, 13.0 gr% in 18 subjects with macroadenomas of 21–40 mm, and 12.4 gr% in 7 patients with giant prolactinomas (>40 mm). In 22 men with normal follow-up testosterone, current HGB levels measured 14.5 gr%, but only 12.8 gr% in 9 men with current low testosterone (P < 0.0005). In men with macroprolactinomas, anemia is common. It is associated with hypogonadism and tumor size, and improves following treatment that normalizes PRL and increases testosterone.

Keywords

Anemia Cabergoline Hemoglobin Hypogonadism Prolactinoma Testosterone 

References

  1. 1.
    Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325–331CrossRefPubMedGoogle Scholar
  2. 2.
    Klibanski A (2010) Clinical practice. Prolactinomas. N Engl J Med 362:1219–1226CrossRefPubMedGoogle Scholar
  3. 3.
    Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046–1052CrossRefPubMedGoogle Scholar
  4. 4.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107CrossRefPubMedGoogle Scholar
  5. 5.
    Nishioka H, Haraoka J, Akada K, Azuma S (2002) Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology 44:407–410CrossRefPubMedGoogle Scholar
  6. 6.
    Nishioka H, Haraoka J, Akada K (2003) Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 59:386–390CrossRefPubMedGoogle Scholar
  7. 7.
    Walsh JP, Pullan PT (1997) Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med 27:385–390PubMedGoogle Scholar
  8. 8.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053–3057CrossRefPubMedGoogle Scholar
  9. 9.
    Gillman MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534CrossRefGoogle Scholar
  10. 10.
    Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardo G (2004) Outcome of cabergoline treatment in men with prolactinoma: effect of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704–1711CrossRefPubMedGoogle Scholar
  11. 11.
    Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinomas: study of 12 men. Eur J Endocrinol 156:225–231CrossRefPubMedGoogle Scholar
  12. 12.
    Hulting AL, Muhr C, Lundberg PO, Werner S (1985) Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand 217:101–109CrossRefPubMedGoogle Scholar
  13. 13.
    Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws ER Jr (2003) Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 98:974–977CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, Valenti G, Ershler WBM, Guralnik JM, Longo DL (2006) Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166:1380–1388CrossRefPubMedGoogle Scholar
  15. 15.
    Gold AP, Michael AF Jr (1959) Congenital adrenal hyperplasia associated with polycythemia. Pediatrics 23:727–730PubMedGoogle Scholar
  16. 16.
    Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350:482–492CrossRefPubMedGoogle Scholar
  17. 17.
    Azen EA, Shahidi NT (1977) Androgen dependency in acquired aplastic anemia. Am J Med 63:320–324CrossRefPubMedGoogle Scholar
  18. 18.
    Shimoda K, Shide K, Kamezaki K, Okamura T, Harada N, Kinukawa N, Ohyashiki K, Niho Y, Mizoguchi H, Omine M, Ozawa M, Haradaa M (2007) The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol 85:338–343CrossRefPubMedGoogle Scholar
  19. 19.
    Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670–2677CrossRefPubMedGoogle Scholar
  20. 20.
    Leberbauer C, Boulme F, Unfried G, Huber J, Beug H, Mullner EW (2005) Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 105:85–94CrossRefPubMedGoogle Scholar
  21. 21.
    Fried W, Jonasson O, Lang G, Schwartz F (1973) The hematologic effect of androgen in uremic patients. Study of packed cell volume and erythropoietin responses. Ann Intern Med 79:823–827PubMedGoogle Scholar
  22. 22.
    Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ (1991) Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17:29–33PubMedGoogle Scholar
  23. 23.
    Woody MA, Welniak LA, Sun R, Tian ZG, Henry M, Richards S, Raziuddin A, Longo DL, Murphy WJ (1999) Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Exp Hematol 27:811–816CrossRefPubMedGoogle Scholar
  24. 24.
    Richards SM, Murphy WJ (2000) Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol 109:56–62CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ilan Shimon
    • 1
    • 2
  • Carlos Benbassat
    • 1
    • 2
  • Gloria Tzvetov
    • 1
    • 2
  • Simona Grozinsky-Glasberg
    • 1
    • 2
  1. 1.Institute of Endocrinology, Beilinson HospitalRabin Medical CenterPetah-TiqvaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations